News + Font Resize -

Waters' Synapt Mass Spectrometry to hasten drug discovery
Our Bureau, Bangalore | Wednesday, January 23, 2008, 08:00 Hrs  [IST]

Waters, the lab instrumentation major, has launched Synapt Mass Spectrometry (MS) system in India which can hasten drug discovery efforts at the research labs of pharma and biotech companies. The product helps to accelerate and improve the quality of laboratory analysis with the objective of advancing research and reducing time-to-market.

The next-generation quadrupole orthogonal acceleration (oa) time-of-flight (Tof) mass spectrometry (MS) platform is now a key part of Waters' strategy to enhance the quality and productivity of life science and drug discovery and development workflows.

Besides, the Synapt MS system is the only platform which provides an upgrade pathway to the high definition mass spectrometry system, enabling researchers to analyze samples differentiated by size, shape and charge, as well as mass, ultimately providing new capabilities that can help them meet future requirements.

"Confident sample identification, detailed characterization and increased productivity are primary requirements for intelligent mass spectrometry based solutions in key biomedical applications such as proteomics, metabonomic profiling, biomarker discovery/validation and pharmaceutical R&D," said Brian W. Smith, vice president, Mass Spectrometry Operations for the Waters Division.

Synapt MS is a central component of Waters' system level solutions combining acquity ultra performance LC separations, exact mass MS data acquisition and 'chemically intelligent' MassLynx Informatics designed to generate high quality, comprehensive data from complex biological samples, maximize confidence in results and enable scientists to make better informed decisions.

It also offers versatile and flexible to determine the spatial localization of drugs, metabolites and peptides in biological tissues with high specificity and sensitivity. It enables higher number of candidates to be evaluated in the drug discovery phase, leading to more rigorous selection of compounds for ongoing development.

"A unique aspect of the Synapt MS System is that it is 'HDMS-ready'. Our customers will be able to upgrade their systems to incorporate the unique High Definition MS capabilities when they require more powerful solutions to meet their future goals, effectively future-proofing their laboratories," added Smith.

The product has been used by the Swedish-based biotechnology firm Medivir AB to hasten its drug discovery efforts in the area of protease inhibitor research and eventually help patients who suffer with herpes, hepatitis C, HIV, osteoporosis, osteoarthritis, and high blood pressure.

Post Your Comment

 

Enquiry Form